Search research articles
Contact Us
Filters
Showing results (171-180 of 197) with videos related to
Page
of 20
Sort By:
American Journal of Clinical Oncology
|
April 1, 1991
Etoposide and mitomycin in the treatment of non-small-cell lung cancer. A phase I-II evaluation
D S Ettinger, J D Bitran, R L Comis, et al.
British Journal of Cancer
|
July 19, 2012
Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer
C Nabhan, D Villines, T V Valdez, et al.
Cancer
|
January 1, 1977
Survival of patients with localized histiocytic lymphoma
J D Bitran, J Kinzie, D L Sweet, et al.
Cancer Treatment Reports
|
September 1, 1976
Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP)--effective four-drug combination chemotherapy for metastatic non-oat cell bronchogenic carcinoma
J D Bitran, R K Desser, T R DeMeester, et al.
Seminars in Oncology
|
August 1, 1995
Paclitaxel and ifosfamide: a multicenter phase I study in advanced non-small cell lung cancer
P C Hoffman, S A Krauss, L C Drinkard, et al.
Seminars in Oncology
|
October 1, 1994
A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design
E E Vokes, L C Drinkard, B L Samuels, et al.
Journal of Surgical Oncology
|
January 1, 1983
Multimodality therapy of stage III adenocarcinoma of the breast
J D Bitran, R K Desser, D Schifeling, et al.
The Cancer Journal From Scientific American
|
November 1, 1995
A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer
G A Masters, L C Drinkard, P C Hoffman, et al.
Cancer Treatment Reports
|
March 1, 1978
Combined modality therapy for stage IIIMO non-oat cell bronchogenic carcinoma
J D Bitran, R K Desser, T DeMeester, et al.
Cancer
|
July 1, 1984
Combined modality therapy for Stage IIIMO non-small cell lung cancer. A five-year experience
P J Madej, J D Bitran, H M Golomb, et al.
Page
of 20
Search research articles
Search
Showing results (171-180 of 197) with videos related to
Sort By:
Page
of 20
American Journal of Clinical Oncology
|
April 1, 1991
Etoposide and mitomycin in the treatment of non-small-cell lung cancer. A phase I-II evaluation
D S Ettinger, J D Bitran, R L Comis, et al.
British Journal of Cancer
|
July 19, 2012
Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer
C Nabhan, D Villines, T V Valdez, et al.
Cancer
|
January 1, 1977
Survival of patients with localized histiocytic lymphoma
J D Bitran, J Kinzie, D L Sweet, et al.
Cancer Treatment Reports
|
September 1, 1976
Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP)--effective four-drug combination chemotherapy for metastatic non-oat cell bronchogenic carcinoma
J D Bitran, R K Desser, T R DeMeester, et al.
Seminars in Oncology
|
August 1, 1995
Paclitaxel and ifosfamide: a multicenter phase I study in advanced non-small cell lung cancer
P C Hoffman, S A Krauss, L C Drinkard, et al.
Seminars in Oncology
|
October 1, 1994
A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design
E E Vokes, L C Drinkard, B L Samuels, et al.
Journal of Surgical Oncology
|
January 1, 1983
Multimodality therapy of stage III adenocarcinoma of the breast
J D Bitran, R K Desser, D Schifeling, et al.
The Cancer Journal From Scientific American
|
November 1, 1995
A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer
G A Masters, L C Drinkard, P C Hoffman, et al.
Cancer Treatment Reports
|
March 1, 1978
Combined modality therapy for stage IIIMO non-oat cell bronchogenic carcinoma
J D Bitran, R K Desser, T DeMeester, et al.
Cancer
|
July 1, 1984
Combined modality therapy for Stage IIIMO non-small cell lung cancer. A five-year experience
P J Madej, J D Bitran, H M Golomb, et al.
Page
of 20